Exploring a new definition of hypertension: A report from the American Society of Hypertension Annual Meeting, May 14-18, 2005, San Francisco, CA

Reviews in Cardiovascular Medicine

Volumn 6, Issue 3, 2005, Pages 164-172

  Weber, Michael A ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Aging; Blood pressure; Hypertension; Obesity; Renin angiotensin system

Indexed keywords

CHLORTALIDONE; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RENIN;

AGING; ANTIHYPERTENSIVE THERAPY; ARTERY COMPLIANCE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DYSLIPIDEMIA; EARLY DIAGNOSIS; ETHNOLOGY; FAMILY HISTORY; GENETIC HETEROGENEITY; GLUCOSE INTOLERANCE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MICROALBUMINURIA; MORTALITY; OBESITY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR;

EID: 26944490725     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease: overall findings and differences by age for 316,099 white men. Arch Intern Med. 1992;152:56-64.
2. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. Age-specific relevance of usual BP to vascular mortality: a meta-analysis of individual data for one million adults in 60 prospective studies. Lancet. 2002; 14:1903-1913.
3. Staessen JA, Gasowski, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcomes trials. Lancet. 2000;104:865-872.
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
5. Hansson L, Zanchetti A, Carruthers S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
6. Julius S, Kjeldsen S, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2003;363:2022-2031.
7. Neutel JM, Smith DHG, Graettinger WF, et al. Metabolic characteristics of hypertension: importance of positive family history. Am Heart J. 1993;126:924-929.
8. Weber MA. Role of hypertension in coronary artery disease. Am J Nephrol. 1996;16:210-216.
9. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
10. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the Management of Arterial Hypertension. J Hypertens. 2003;21:1011-1054.
11. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997,157:2413-2446.
12. Hajjar J, Kotchen TA. Trends in prevalence, awareness, treatment and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206.
13. Brunner HR, Laragh JH, Baer L, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972;286:441-449.
14. Alderman MH, Madhaven S, Ooi WL, et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:1098-1104.
15. Laragh JH. Vasoconstriction volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med. 1973;55:261-274.
16. Buhler FR, Laragh JH, Baer L, et al. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diabetes. N Engl J Med. 1972;287:1209-1214.
17. Weber MA, Drayer JI, Rev A, et al. Disparate patterns of aldosterone response during diuretic treatment of hypertension. Ann Intern Med. 1977;87:558-563.
18. Carman WJ, Barrett-Connor E, Sowers M, Khaw K. Hypertension/risk factors: higher risk of cardiovascular mortality among lean hypertensive individuals in Tecumesh, Michigan. Circulation. 1994;89:703-711.
19. Weber MA, Neutel JM, Smith DHG. Contrasting clinical properties and exercise responses in obese and lean hypertensive patients. J Am Coll Cardiol. 2001;37:169-174.
20. Wassertheil-Smoller S, Fann C, Allman RM, et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Arch Intern Med. 2000;160:494-500.
21. Agrawal B, Berger A, Wolf K, et al. Microalbuminuria screening by reagent predicts cardiovascular risk in hypertension. J Hypertens. 1996;14:223-228.
22. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
23. Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Management of high blood pressure in African Americans. Arch Intern Med. 2003;163: 525-541.